Beyond radiation, and despite a lack of momentum from early-stage clinical trials (1), targeting the intratumor cGAS/STING axis with specific agonists of STING (e.g., analogs or derivatives of cGAMP) remains of interest in immunologically quiescent cancer types, such as gliomas (20). Here, CGAS is linked to glioma.